| ||
| Study Confirms Long-Lasting Benefit Of Trastuzumab (Herceptin) For Women With ... Medical News Today (press release) Trastuzumab is a monoclonal antibody developed to block the cancer-causing activity of the HER2 protein and has been shown to prolong survival in patients with advanced breast cancer. The HERA trial was designed to establish whether trastuzumab could ... See all stories on this topic » | ||
| Celgene, Elan settle Abraxane case for $78M; Health groups ask Novartis to ... FiercePharma > Celgene has agreed to pay Elan $78 million to settle a patent infringement lawsuit over the Celgene breast cancer drug Abraxane. In return, Celgene gets a worldwide license to several of Elan's related patents. Report > Novartis has been urged to ... See all stories on this topic » | ||
| Europe Factors-Shares set to rise as crude eases from high Reuters ... 5.2 percent to 278.6 million euros ($384.3 million). [ID:nLDE71N1XJ] Roche's Genentech has won a second chance to convince US regulators that its Avastin drug is a safe and effective treatment for breast cancer. (Reporting by Harpreet Bhal) See all stories on this topic » | ||
| Personalized Medicine: Towards Customized Treatment of Breast Cancer Science Daily (press release) Women with locally advanced breast cancer who are undergoing treatment at Oslo University Hospital are now offered chemotherapy in combination with Avastin. Samples of their tissue, blood and bone marrow are collected for future analysis. ... See all stories on this topic » | ||
| FDA Grants Genentech a Hearing on Avastin's Use for Metastatic Breast Cancer ... VAdvert Press Center (press release) Avastin is also approved for first- and second-line treatment of metastatic colorectal cancer in combination with intravenous 5-FU-based chemotherapy, first-line treatment of unresectable, locally advanced, recurrent or metastatic, non-squamous, ... See all stories on this topic » |
| ||
| Onyx Misses Q4; Gives Outlook By Zacks Investment Research The companies recently started enrolling patients in a phase III trial ( RESILIENCE) that will evaluate Nexavar in combination with capecitabine (oral chemotherapeutic agent) for the treatment of advanced breast cancer. ... DailyMarkets.com - http://www.dailymarkets.com/ | ||
| Husband who gave wife lethal injection says he was following ... By Nancy Lentz Abortion; Accidents; Addictions; Advance Care Planning and Advance Directives; Alcohol; Animals; Artifical Reproductive Technology; Best Interests; Bioethics; Biomedical Research; Biotechnology; Case Law; Children; Chronic Disease ... Pain ; Post-Coma Unresponsiveness and Vegetative States; Pregnancy; Preventative care ; Principle-Based Ethics; Privacy & Health Information; Product Liability; Public Health; Refugees; Refusing Treatment; Registration and Professionalism ... Ethics & Health Law News - http://ehln.org/ | ||
| Holy Family Medical Center Women's Imaging Center Offers Free ... By Kristy Lockhart Getting regular screening tests is the best way for women to lower their risk of breast cancer. Screening tests can find breast cancer early, when it's most treatable. According to the latest statistics from the Centers for Disease Control ... remodeled Women's Imaging Center now offers the latest advanced mammography technologies to address the unique health care needs of women. "We provide highly specialized diagnostic breast care in a caring, compassionate environment. ... TribLocal - Des Plaines - http://triblocal.com/des-plaines/ | ||
| FDA grants meeting on Avastin for breast cancer | KVAL CBS 13 ... The Food and Drug Administration has granted Swiss drugmaker Roche a first-of-a- kind public hearing to defend the effectiveness of its drug Avastin for treating breast cancer, just months after the agency ruled that the drug is ineffective for that use. ... When infusion charges are included, a year's treatment with Avastin can run more than $100000, though Roche caps spending at $57000 per year for patients who meet certain financial criteria. ... KVAL - News - Health - http://www.kval.com/news/health | ||
| Medtronic Bypasses the Hospital Group Buyer - NYTimes.com By By DUFF WILSON F.D.A. Grants Hearing on Avastin as Treatment for Breast Cancer. The Food and Drug Administration has granted a hearing for Genentech to argue in favor of preserving the approval of its drug Avastin as a treatment for breast cancer. February 23 ... When the Battle With Cancer Can't Be Won. A new booklet from the American Society of Clinical Oncology lays out the options when cancer is found to be advanced. ... Prescriptions - http://prescriptions.blogs.nytimes.com/ |
Tip: Use site restrict in your query to search within a site (site:nytimes.com or site:.edu). Learn more.
Remove this alert.
Create another alert.
Manage your alerts.
No comments:
Post a Comment